Company intelligence / Profile preview

Zolovax

Olathe, Kansas, United States

Ownership: Private
Development stage: Other

Overview

Zolovax is a biotechnology company focused on the development of a vaccine to prevent Zika virus infection. The company's lead candidate is a recombinant subunit vaccine designed to provide a safe and effective solution to the global health threat posed by the Zika virus, particularly its link to birth defects. Zolovax aims to leverage its specialized focus on flaviviruses to address unmet needs in infectious disease prevention. The company is currently in the pre-clinical stage of development, working toward advancing its candidate into human clinical trials.

Therapeutic areas: Infectious Diseases
Modalities: VaccineRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Zolovax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zolovax.

Explore the full profile